Ardena boosts its API manufacturing capabilities by acquiring Syntagon

| By | API, CDMO, Drug Manufacturing
0
48

Contract development and manufacturing organisation (CDMO) Ardena has acquired Syntagon, a leading contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients.

The acquisition, which is the CDMO’s first outside the Benelux region, expands its drug substance manufacturing capacity and means that bigger batch sizes up to 100 kg can now be handled by Ardena. Syntagon also adds specialist expertise in GMP chromatographic purification processes to the group.

The announcement follows Ardena’s acquisition of ChemConnection in March 2018 and is part of its strategy to form a leading integrated drug development company and reach the €35m sales mark this year.

Established in 1999, Syntagon has sites in Sweden and Latvia and employs 30 people. This latest acquisition brings the total number of Ardena facilities to six, including its headquarters in Ghent, Belgium and three sites in the Netherlands (Oss, Amsterdam and Assen).

Ardena was formed in 2017, following the merging of three companies with complementary capabilities: Pharmavize in Belgium, and Crystallics and Analytical Biochemical Laboratory (ABL) in the Netherlands. With the acquisitions of ChemConnection and Syntagon in 2018, Ardena now employs more than 225 scientists.

SOURCE: ardena
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.